Key result
Empirical antibiotics offer limited benefit in unconfirmed heart failure infections and risk potential harms.
Why the study?
Patients with heart failure are vulnerable to infections that cause acute decompensation, but overlapping symptoms frequently lead to unconfirmed empirical antibiotic use associated with extended hospital stays, drug toxicity, and antibiotic resistance.
In patients with heart failure, while early targeted antibiotic therapy improves outcomes in confirmed infections, unnecessary empirical antibiotics offer limited benefit and may cause harm, highlighting the need for careful diagnostic evaluation and antimicrobial stewardship.
Infections commonly cause acute decompensation and poor outcomes in heart failure (HF), a major global health burden. Patients with heart failure are particularly vulnerable to infections related to the respiratory, urinary, skin, and devices because of systemic inflammation, immune dysfunction, changes in the gut barrier, and repeated exposure to healthcare facilities. The use of empirical antibiotics without confirmation due to overlapping symptoms between infection and heart failure is frequently associated with extended hospital stays, drug toxicity, and antibiotic resistance. While early targeted therapy improves outcomes in confirmed infections, evidence points to limited benefit and possible harm from unnecessary antibiotics. To maximize management in this susceptible population, careful diagnostic evaluation, stewardship, and customized prescribing are crucial.
No takes yet. Share an insight, caveat, or question.
Kaur et al. (2026) conducted a review in Heart failure. Antibiotics was evaluated. Empirical antibiotics without confirmed infection in heart failure offer limited benefit and may cause extended hospital stays, toxicity, and resistance.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: